Q3 Gross Sales at Rs 134,369 million up 10.5 per cent YoY

Sun Pharmaceutical Industries reported financials for the third quarter ending December 31, 2024.

Highlights of Q3FY25 consolidated financials*

·         Gross sales at Rs 134,369 million, growth of 10.5 per cent

·         India formulation sales at Rs 43,004 million, up 13.8 per cent

·         US formulation sales at $474 million, down 0.7 per cent

·         Global Specialty sales at $370 million, including the $45 million milestone. Ex-milestones, up 17.5 per cent

·         Global Specialty sales, ex-milestone, accounted for 21 per cent of Q3FY25 sales

·         Emerging Markets formulation sales at $277 million, up 10.1 per cent

·         Rest of World formulation sales at $259 million, up 21 per cent

·         R&D investments at Rs 8,450 million compared to Rs 8,245 million for Q3FY24

·         EBITDA at Rs 40,090 million (including other operating revenues), up 15.3 per cent, with a resulting EBITDA margin of 29.3 per cent·         

·  Adjusted net profit (excluding the exceptional items) for Q3FY25 was Rs 32,196 million, up 24.1 per cent. Reported net profit for Q3FY25 was Rs 29,034 million compared to Rs 25,238 million during Q3FY24

Highlights of 9mFY25 consolidated financials

·         Gross sales at Rs 392,257 million, growth of 9.1 per cent

·         India formulation sales at Rs. 127,100 million, up 13.7 per cent

·         US formulation sales at $1,457 million, up 5.7 per cent

·         Emerging Markets formulation sales at $ 854 million, up 7.2 per cent

·         Rest of World formulation sales at US 647 million, up 5.2 per cent

·         EBITDA at Rs 115,556 million (including other operating revenues), up 15.7 per cent, with a resulting EBITDA margin of 29.2 per cent

·         Net profit for 9mFY25 was Rs 87,792 million. Like for like, adjusted net profit at Rs 90,953 million, up 24.3 per cent

The Board has declared an interim dividend of Rs. 10.50 per share for the year FY25 against Rs. 8.50 per share interim dividend for the previous year.

Dilip Shanghvi, CMD, Sun Pharma, said, “Our performance in the quarter showed all-round improvement. Product sales in Global Specialty crossed 1/5th of overall sales. Our market share gain in India has been driven by industry leading volume growth. Emerging Markets demonstrated strong performance despite currency challenges across geographies. All our businesses remain well positioned for the future.”